The NIH has a notice for comments on proposed licenses of several patents relating to the “Production of Attenuated Respiratory Syncytial Virus Vaccines”. See: https://federalregister.gov/a/2016-03486
We asked Peter Soukas, a Senior Technology Licensing Specialist in the Technology Transfer and Intellectual Property Office, at the National Institute of Allergy and Infectious Diseases (NIAID), these questions:
- What provisions exist in the license to protect US residents against excessive or unreasonable pricing?
- What provisions exist in the license to ensure access in developing countries?
- What are the royalty arrangements?
- How much money did the government spend on these inventions?
- How much do you reckon the company receiving the license will have to spend on further development?